205 related articles for article (PubMed ID: 35865463)
1. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing
Varughese LA; Bhupathiraju M; Hoffecker G; Terek S; Harr M; Hakonarson H; Cambareri C; Marini J; Landgraf J; Chen J; Kanter G; Lau-Min KS; Massa RC; Damjanov N; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
Front Oncol; 2022; 12():859846. PubMed ID: 35865463
[TBL] [Abstract][Full Text] [Related]
2. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation.
Lau-Min KS; Varughese LA; Nelson MN; Cambareri C; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
BMC Cancer; 2022 Jan; 22(1):47. PubMed ID: 34996412
[TBL] [Abstract][Full Text] [Related]
3. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
Reizine N; Vokes EE; Liu P; Truong TM; Nanda R; Fleming GF; Catenacci DVT; Pearson AT; Parsad S; Danahey K; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Ther Adv Med Oncol; 2020; 12():1758835920974118. PubMed ID: 33414846
[TBL] [Abstract][Full Text] [Related]
4. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese LA; Lau-Min KS; Cambareri C; Damjanov N; Massa R; Reddy N; Oyer R; Teitelbaum U; Tuteja S
Pharmacotherapy; 2020 Nov; 40(11):1108-1129. PubMed ID: 32985005
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
Glewis S; Lingaratnam S; Krishnasamy M; H Martin J; Tie J; Alexander M; Michael M
J Oncol Pharm Pract; 2024 Jan; 30(1):30-37. PubMed ID: 37021580
[TBL] [Abstract][Full Text] [Related]
6. Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.
Glewis S; Krishnasamy M; Lingaratnam S; Harris S; Underhill C; Georgiou C; Warren M; Campbell R; IJzerman M; Fagery M; Campbell I; Martin JH; Tie J; Alexander M; Michael M
Clin Transl Sci; 2023 Dec; 16(12):2700-2708. PubMed ID: 37877594
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
Fragoulakis V; Roncato R; Bignucolo A; Patrinos GP; Toffoli G; Cecchin E; Mitropoulou C
Pharmacol Res; 2023 Nov; 197():106949. PubMed ID: 37802427
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
Luczak TS; Schillo PJ; Renier CM; Waring SC; Friday BB
J Oncol Pharm Pract; 2022 Jun; 28(4):842-849. PubMed ID: 33853470
[TBL] [Abstract][Full Text] [Related]
9. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Morris SA; Moore DC; Musselwhite LW; Lopes KE; Hamilton A; Steuerwald N; Hanson SL; Larck C; Swift K; Smith M; Kadakia KC; Chai S; Hwang JJ; Patel JN
Am J Health Syst Pharm; 2023 Sep; 80(19):1342-1349. PubMed ID: 37235983
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
[TBL] [Abstract][Full Text] [Related]
11. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Pasternak AL; Seda R; Lipa J; McDevitt RL; Crysler OV; Swiecicki PL; Schneider BJ; Vanderwerff B; Henry NL; Krauss JC; Sahai V; Hertz DL
Clin Pharmacol Ther; 2023 Aug; 114(2):356-361. PubMed ID: 37163252
[TBL] [Abstract][Full Text] [Related]
12. Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing.
Vest BM; Wray LO; Brady LA; Thase ME; Beehler GP; Chapman SR; Hull LE; Oslin DW
BMC Psychiatry; 2020 Oct; 20(1):518. PubMed ID: 33115428
[TBL] [Abstract][Full Text] [Related]
13. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial.
Oslin DW; Chapman S; Duvall SL; Gelernter J; Ingram EP; Kranzler HR; Lehmann LS; Lynch JA; Lynch KG; Pyne JM; Shih MC; Stone A; Thase ME; Wray LO
Contemp Clin Trials; 2021 Feb; 101():106247. PubMed ID: 33316457
[TBL] [Abstract][Full Text] [Related]
14. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
15. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
[No Abstract] [Full Text] [Related]
16. Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial.
Hassett MJ; Wong S; Osarogiagbon RU; Bian J; Dizon DS; Jenkins HH; Uno H; Cronin C; Schrag D;
Trials; 2022 Jun; 23(1):506. PubMed ID: 35710449
[TBL] [Abstract][Full Text] [Related]
17. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V; De Bellis E; Manzo V; Sabbatino F; Iannello F; Dal Piaz F; Izzo V; Charlier B; Stefanelli B; Torsiello M; Iannaccone T; Coglianese A; Colucci F; Pepe S; Filippelli A
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899374
[TBL] [Abstract][Full Text] [Related]
18. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review.
B Tata E; A Ambele M; S Pepper M
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32858798
[TBL] [Abstract][Full Text] [Related]
19. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
20. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
